NETTER-2 — First-Line [177Lu]Lu-DOTA-TATE Plus Octreotide LAR in Advanced Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors

Phase 3 · 2024 · Neuroendocrine Tumors

Design

Randomized open-label to first-line [177Lu]Lu-DOTA-TATE plus octreotide LAR vs high-dose octreotide LAR alone.

Population

Newly diagnosed advanced, somatostatin-receptor-positive grade 2/3 gastroenteropancreatic neuroendocrine tumors.

Primary Endpoint

progression-free survival (PFS)

Key Result

Median PFS 22.8 vs 8.5 mo (HR 0.276).

Guideline Impact

Supported first-line [177Lu]Lu-DOTA-TATE for advanced grade 2/3 gastroenteropancreatic neuroendocrine tumors